Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients.

Pharmacological research - 1 Jan 2021

Del Re Marzia, Crucitta Stefania, Lorenzini Giulia, De Angelis Claudia, Diodati Lucrezia, Cavallero Diletta, Bargagna Irene, Cinacchi Paola, Fratini Beatrice, Salvadori Barbara, Ghilli Matteo, Roncella Manuela, Fontana Andrea, Danesi Romano, Cucchiara Federico

Abstract excerpt

BACKGROUND: PI3K pathway hyperactivation due to PIK3CA mutations contributes to endocrine resistance, and PIK3CA is one of the most frequently mutated genes in breast cancer (BC), occurring approximately 40 % of HR+, HER2- advanced BC (ABC). Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) have changed the treatment landscape of HR+, HER2- ABC. Putative mechanisms of resistance to CDK4/6i have been...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Class I Phosphatidylinositol 3-Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclin-Dependent Kinase 4

Share to Cyclin-Dependent Kinase 6

Share to Drug Resistance, Neoplasm

Share to Liquid Biopsy

Share to Pilot Projects

Share to Progression-Free Survival

Source

Identifiers

PMID: 33049397
DOI: 10.1016/j.phrs.2020.105241

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients.PMID 33049397Read ↗

Circulating PIK3CA mutation detection at diagnosis in non-metastatic inflammatory breast cancer patients.Semantic proximity Read ↗

Biomarkers of Response and Resistance to CDK4/6 Inhibitors in Breast Cancer: Hints from Liquid Biopsy and microRNA ExplorationSemantic proximity Read ↗

PIK3CA mutation detection by circulating tumor cell sequencing guides the effective PI3K inhibitor treatment of a patient with hormone receptor-positive breast cancer transformed into triple-negative breast cancer: A case report.Semantic proximity Read ↗

Integrating PIK3CA Testing into Clinical Practice for Advanced HR+/HER2- Breast Cancer: An Expert Consensus.Semantic proximity Read ↗

PIK3CA mutations in breast cancerSemantic proximity Read ↗

PIK3CA mutations in endocrine-resistant breast cancer.Semantic proximity Read ↗

[What's new liquid biopsy-PIK3CA testing in breast cancer].Semantic proximity Read ↗

Sensitive and robust liquid biopsy-based detection of PIK3CA mutations in hormone-receptor-positive metastatic breast cancer patients.Semantic proximity Read ↗

PIK3CA somatic alterations in invasive breast cancers: different spectrum from Caucasians to Chinese detected by next generation sequencing.Semantic proximity Read ↗

Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.Semantic proximity Read ↗

PIK3CA-mutations in breast cancer.Semantic proximity Read ↗

Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.